Development of nitroalkene-based inhibitors to target STING-dependent inflammation
Redox Biology · 2024-08 · 74 · 103202
DOI: 10.1016/j.redox.2024.103202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Redox Biology, 2024-08. Verfasst von Fei Chang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Hauptthemen laut MEDLINE: Membrane Proteins, Inflammation, Alkenes, Nitro Compounds. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Stimulator of Interferon Genes (STING) is essential for the inflammatory response to cytosolic DNA. Despite that aberrant activation of STING is linked to an increasing number of inflammatory diseases, the development of inhibitors has been challenging, with no compounds in the pipeline beyond the preclinical stage. We previously identified endogenous nitrated fatty acids as novel reversible STING inhibitors. With the aim of improving the specificity and efficacy of these compounds, we developed and tested a library of nitroalkene-based compounds for in vitro and in vivo STING inhibition. The structure-activity relationship study revealed a robustly improved electrophilicity and reduced degrees of freedom of nitroalkenes by conjugation with an aromatic moiety. The lead compounds CP-36 and CP-45, featuring a β-nitrostyrene moiety, potently inhibited STING activity in vitro and relieved STING-dependent inflammation in vivo. This validates the potential for nitroalkene compounds as drug candidates for STING modulation to treat STING-driven inflammatory diseases, providing new robust leads for preclinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
- Department of Biomedicine, Aarhus University, 8000, Aarhus C, Denmark.
- Department of Physiology, Morehouse School of Medicine, Atlanta, GA, 30310, USA.
- Laboratorio de Enzimología, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo, 11400, Uruguay; Centro de Investigaciones Biomédicas (CEINBIO), Universidad de la República, Mon…
- Translational Autoinflammatory Disease Studies Unit, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20850, USA.
- Department of Physiology, Morehouse School of Medicine, Atlanta, GA, 30310, USA. Electronic address: lvillacortaperez@msm.edu.
Förderung
- NIGMS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Chang, F., Gunderstofte, C., Colussi, N., Pitts, M., Salvatore, S. R., Thielke, A. L., Turell, L., Alvarez, B., Goldbach-Mansky, R., Villacorta, L., Holm, C. K., Schopfer, F. J., & Hansen, A. L. (2024). Development of nitroalkene-based inhibitors to target STING-dependent inflammation. Redox Biology, 74, 103202. https://doi.org/10.1016/j.redox.2024.103202
Vancouver
Chang F, Gunderstofte C, Colussi N, Pitts M, Salvatore SR, Thielke AL, et al. Development of nitroalkene-based inhibitors to target STING-dependent inflammation. Redox Biology. 2024;74:103202. doi:10.1016/j.redox.2024.103202
BibTeX
@article{Chang2024,
author = {Chang, Fei and Gunderstofte, Camilla and Colussi, Nicole and Pitts, Mareena and Salvatore, Sonia R and Thielke, Anne L and Turell, Lucia and Alvarez, Beatriz and Goldbach-Mansky, Raphaela and Villacorta, Luis and Holm, Christian K and Schopfer, Francisco J and Hansen, Anne Louise},
title = {Development of nitroalkene-based inhibitors to target STING-dependent inflammation},
journal = {Redox Biology},
year = {2024},
volume = {74},
pages = {103202},
doi = {10.1016/j.redox.2024.103202}
}
EUVIMED